Cite
HARVARD Citation
Qin, S. et al. (n.d.). 2353 Data from a phase Ib/II trial of the oral c-Met inhibitor tepotinib (MSC2156119J) as first-line therapy in Asian patients with advanced hepatocellular carcinoma. European journal of cancer. pp. S452-S453. [Online].